Executive summary
Japan prescription drug market in FY2030 by future
Japan · ¥ tn at NHI prices · FY2025 actual vs midpoint of each FY2030 range
Source: [IQVIA May 2026]; [Kira estimates] for FY2030
Plan Japan as a ¥11-13 tn market in FY2030: enter with new, priority-review drugs and biosimilars that gain from the rules, not with mature products that lose 4-6% of price a year.
IQVIA May 2026 = IQVIA Japan · IQVIA Nov 2025 = IQVIA Japan · Jiho Oct 2026 = Jiho · MHLW Mar 2026 = Ministry of Health · Kira estimates = KIRA analyst triangulation from the anchors named on each page
The market reached a record ¥11.8 tn in FY2025, but the industry's own forecast adds only ¥0.1 tn by FY2030
Fifth year of growth; the forecast made six months earlier had expected a much lower FY2025 base.
¥11.8 tn
Prescription market, FY2025 at NHI prices, +3.1%
[IQVIA May 2026]
¥11.9 tn
Industry forecast for FY2030 (CAGR 1.2%)
[IQVIA Nov 2025]
¥6.06 tn
Drug fees in pharmacy dispensing, FY2024
[MHLW 2025 dispensing]
90.6%
Generic volume share in pharmacies, end-FY2024
[MHLW 2025 dispensing]
Japan prescription drug market at NHI prices
Japan · ¥ tn · fiscal years (April-March) · FY2030 = industry forecast
Source: [IQVIA 2025]; [IQVIA May 2026]; [IQVIA Nov 2025]
The FY2025 jump came from new oncology and metabolic drugs; the forecast assumes price cuts absorb most of the volume growth after that.
IQVIA 2025 = IQVIA Japan · IQVIA May 2026 = IQVIA Japan · IQVIA Nov 2025 = IQVIA Japan · MHLW 2025 dispensing = MHLW
The answer in three lines
Volume grows, price falls. The market reached a record ¥11.8 tn in FY2025, up 3.1% [IQVIA May 2026], while the April 2026 revision cut list prices by 4.02% on average [MHLW Mar 2026].
It stays a flat-to-slow market. We put FY2030 at ¥11.0-13.6 tn [Kira estimates]; the industry baseline is ¥11.9 tn [IQVIA Nov 2025].
Pricing rules decide the spread. Whether the FY2027 off-year cut goes ahead and whether new drugs keep their price [Jiho Oct 2026] matter more than demand.